S. Bouée, C. Emery, A. Samson, J. Gourmelen, C. Bailly et al., Incidence of venous thromboembolism in France: a retrospective analysis of a national insurance claims database

, Thromb J, vol.14, p.4, 2016.

F. A. Anderson, H. B. Wheeler, R. J. Goldberg, D. W. Hosmer, N. A. Patwardhan et al., A Population-Based Perspective of the Hospital Incidence and Case-Fatality Rates of Deep Vein Thrombosis and Pulmonary Embolism: The Worcester DVT Study, Arch Intern Med. 1 mai, vol.151, issue.5, pp.933-941, 1991.

M. Riedel, V. Stanek, J. Widimsky, and I. Prerovsky, Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data, Chest. févr, vol.81, issue.2, pp.151-159, 1982.

S. C. Mathai, H. Ghofrani, E. Mayer, J. Pepke-zaba, S. Nikkho et al., Quality of life in patients with chronic thromboembolic pulmonary hypertension, European Respiratory Journal. 1 août, vol.48, issue.2, pp.526-563, 2016.

S. Noble, R. Lewis, J. Whithers, S. Lewis, and P. Bennett, Long-term psychological consequences of symptomatic pulmonary embolism: a qualitative study, BMJ Open. 2 avr, vol.4, issue.4, p.4561, 2014.

A. A. Ashrani and J. A. Heit, Incidence and cost burden of post-thrombotic syndrome, J Thromb Thrombolysis, vol.28, issue.4, pp.465-76, 2009.

E. Montero-ruiz, B. Utrilla, G. , L. Álvarez, J. et al., Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients, Thromb Res, vol.128, issue.5, pp.440-445, 2011.

M. M. Samama, A. T. Cohen, J. Y. Darmon, L. Desjardins, A. Eldor et al., A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group, N Engl J Med. 9 sept, vol.341, issue.11, pp.793-800, 1999.

J. Fareed, D. Hoppensteadt, J. Walenga, O. Iqbal, Q. Ma et al., Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice, Clin Pharmacokinet, vol.42, issue.12, pp.1043-57, 2003.

P. Boccardo, G. Remuzzi, and M. Galbusera, Platelet dysfunction in renal failure, Semin Thromb Hemost, vol.30, issue.5, pp.579-89, 2004.

W. Lim, F. Dentali, J. W. Eikelboom, and M. A. Crowther, Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency, Ann Intern Med. 2 mai, vol.144, issue.9, pp.673-84, 2006.

L. Pellizzari, R. Facchinetti, L. Corrà, A. Sepe, F. Fantin et al., Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure?, Aging Clin Exp Res. juin, vol.30, issue.6, pp.605-613, 2018.

F. Atiq, P. Van-den-bemt, F. Leebeek, T. Van-gelder, and J. Versmissen, A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency, Eur J Clin Pharmacol. août, vol.71, issue.8, pp.921-930, 2015.

, LOVENOX® (énoxaparine sodique) : mise à jour de l'expression du dosage, de sa posologie dans le traitement de la thrombose veineuse profonde (TVP), et de l'embolie pulmonaire (EP) et de son utilisation en cas d'insuffisance rénale sévère -Lettre aux pro -ANSM : Agence nationale de sécurité du médicament et des produits de santé

D. Sur,

L. Rojas, A. Aizman, D. Ernst, M. P. Acuña, P. Moya et al., Xa Activity After Enoxaparin Prophylaxis In Hospitalized Patients Weighing Less Than Fifty-Five Kilograms

. Bergmann and E. Neuhart, A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The enoxaparin in medicine study group, Thromb Haemost, vol.76, pp.529-534, 1996.

, VII. 2) Engagement de l'investigateur -Recherche n'impliquant pas la personne humaine